Banque Pictet & Cie SA Has $3.97 Million Stake in Exact Sciences Co. (NASDAQ:EXAS)

Banque Pictet & Cie SA trimmed its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 62.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,693 shares of the medical research company’s stock after selling 118,540 shares during the period. Banque Pictet & Cie SA’s holdings in Exact Sciences were worth $3,972,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in EXAS. Thompson Investment Management Inc. lifted its holdings in Exact Sciences by 17.8% during the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company’s stock worth $13,585,000 after purchasing an additional 36,505 shares during the last quarter. WCM Investment Management LLC lifted its holdings in Exact Sciences by 1,153.2% during the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock worth $12,388,000 after purchasing an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. lifted its holdings in Exact Sciences by 67.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock worth $1,994,000 after purchasing an additional 11,800 shares during the last quarter. Zacks Investment Management acquired a new stake in Exact Sciences during the 3rd quarter worth approximately $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Exact Sciences by 59.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock worth $22,868,000 after purchasing an additional 125,192 shares during the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Trading Down 2.5 %

NASDAQ EXAS opened at $49.31 on Friday. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The company has a market cap of $9.13 billion, a price-to-earnings ratio of -42.14 and a beta of 1.24. The business’s fifty day moving average is $56.15 and its 200 day moving average is $60.09.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on EXAS shares. Sanford C. Bernstein lifted their price target on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Piper Sandler lowered their price objective on Exact Sciences from $85.00 to $75.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Jefferies Financial Group raised their price objective on Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Evercore ISI lowered their price objective on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, BTIG Research raised their price objective on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.